Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]
In development [GID-TA10674] Expected publication date: TBC
Search results
548 results
-
-
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488
In development [GID-TA10432] Expected publication date: TBC
-
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442]
In development [GID-TA10672] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer [ID1676]
In development [GID-TA10743] Expected publication date: 17 November 2021
-
Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]
In development [GID-TA10520] Expected publication date: 15 September 2021
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: 13 October 2021
-
Cenobamate for focal onset seizures in epilepsy [ID1553]
In development [GID-TA10661] Expected publication date: 13 October 2021
-
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]
In development [GID-TA10650] Expected publication date: 25 August 2021
-
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]
In development [GID-TA10612] Expected publication date: 21 July 2021
-
Midostaurin for treating advanced systemic mastocytosis ID1573
In development [GID-TA10503] Expected publication date: TBC
-
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]
In development [GID-TA10523] Expected publication date: TBC
-
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]
In development [GID-TA10614] Expected publication date: TBC
-
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
In development [GID-TA10666] Expected publication date: 26 August 2021
-
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
In development [GID-TA10618] Expected publication date: TBC
-
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]
In development [GID-TA10658] Expected publication date: 20 October 2021
-
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
In development [GID-TA10706] Expected publication date: 20 October 2021
-
Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]
In development [GID-TA10719] Expected publication date: 02 February 2022
-
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]
In development [GID-TA10209] Expected publication date: TBC
-
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]
In development [GID-TA10260] Expected publication date: TBC
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]
In development [GID-TA10586] Expected publication date: TBC
-
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]
In development [GID-TA10513] Expected publication date: TBC
-
Ponesimod for treating relapsing multiple sclerosis [ID1393]
In development [GID-TA10556] Expected publication date: 17 November 2021
-
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]
In development [GID-TA10712] Expected publication date: TBC
-
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]
In development [GID-TA10782] Expected publication date: 20 October 2021
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
In development [GID-TA10430] Expected publication date: TBC
-
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
In development [GID-TA10805] Expected publication date: 23 March 2022
-
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]
In development [GID-TA10481] Expected publication date: 18 August 2021
-
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-TA10690] Expected publication date: TBC
-
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]
In development [GID-TA10373] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]
In development [GID-TA10477] Expected publication date: 22 September 2021
-
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1065]
In development [GID-TA10385] Expected publication date: TBC
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]
In development [GID-TA10619] Expected publication date: TBC
-
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]
In development [GID-TA10624] Expected publication date: 23 June 2021
-
Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]
In development [GID-TA10510] Expected publication date: 28 April 2021
-
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: 28 April 2021
-
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]
In development [GID-TA10305] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494
In development [GID-TA10424] Expected publication date: TBC
-
Dapagliflozin for treating chronic kidney disease [ID3866]
In development [GID-TA10808] Expected publication date: 05 January 2022
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: TBC
-
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
In development [GID-TA10420] Expected publication date: 23 June 2021
-
Ozanimod for treating relapsing-remitting multiple sclerosis [ID1294]
In development [GID-TA10299] Expected publication date: 30 June 2021
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-TA10642] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
In development [GID-TA10316] Expected publication date: TBC
-
Budesonide for treating active eosinophilic oesophagitis [ID1202]
In development [GID-TA10372] Expected publication date: 23 June 2021
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]
In development [GID-TA10122] Expected publication date: TBC
-
Romosozumab for treating severe osteoporosis [ID3936]
In development [GID-TA10828] Expected publication date: TBC
-
Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]
In development [GID-TA10526] Expected publication date: 28 April 2021
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]
In development [GID-TA10781] Expected publication date: 22 September 2021